Next Science Ltd
ASX:NXS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.125
0.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Next Science Ltd
Next Science Ltd
Accounts Receivables
Next Science Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Next Science Ltd
ASX:NXS
|
Accounts Receivables
$3.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Nanosonics Ltd
ASX:NAN
|
Accounts Receivables
AU$40.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
15%
|
CAGR 10-Years
22%
|
|
|
Polynovo Ltd
ASX:PNV
|
Accounts Receivables
AU$19.9m
|
CAGR 3-Years
57%
|
CAGR 5-Years
52%
|
CAGR 10-Years
35%
|
|
|
SDI Ltd
ASX:SDI
|
Accounts Receivables
AU$21m
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Accounts Receivables
AU$595.8k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Accounts Receivables
$211.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
Next Science Ltd
Glance View
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
See Also
What is Next Science Ltd's Accounts Receivables?
Accounts Receivables
3.5m
USD
Based on the financial report for Dec 31, 2023, Next Science Ltd's Accounts Receivables amounts to 3.5m USD.
What is Next Science Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
38%
Over the last year, the Accounts Receivables growth was 117%. The average annual Accounts Receivables growth rates for Next Science Ltd have been 1% over the past three years , 38% over the past five years .
You don't have any saved screeners yet
